Ashique Rafique
YOU?
Author Swipe
View article: Risk Factors Associated with MDR and CR Acinetobacter baumannii Carriage among ICU Patients Hospitalized at Hospitals in Pakistan
Risk Factors Associated with MDR and CR Acinetobacter baumannii Carriage among ICU Patients Hospitalized at Hospitals in Pakistan Open
Background: In hospital intensive care units (ICUs) around the world, multidrug-resistant and carbapenem-resistant Acinetobacter baumannii (CRAB) infections pose a serious concern, and this is especially true in developing nations like Pak…
View article: Bacteriological Profile and Antibiotic Sensitivity Pattern of Urinary Tract Infection
Bacteriological Profile and Antibiotic Sensitivity Pattern of Urinary Tract Infection Open
Introduction:Urinary tract infection (UTI) is a common infection that may occur in any part of the urinary system - kidneys, ureters, bladder and urethra. UTIs are caused by a wide range of pathogens, and recurrence rates of UTIs are high.…
View article: Structures of complete extracellular assemblies of type I and type II Oncostatin M receptor complexes
Structures of complete extracellular assemblies of type I and type II Oncostatin M receptor complexes Open
Oncostatin M (OSM) is a unique Interleukin 6 (IL-6) family cytokine that plays pivotal roles in numerous biological events by signaling via two types of receptor complexes. While type I OSM receptor complex is formed by glycoprotein 130 (g…
View article: Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone
Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone Open
View article: Supplementary Fig S7 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S7 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S7
View article: Supplementary Data from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Data from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Table S1
View article: Supplementary Fig S2 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S2 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S2
View article: Supplementary Fig S12 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S12 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S12
View article: Supplementary Fig S3 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S3 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S3
View article: Supplementary Fig S7 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S7 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S7
View article: Supplementary Fig S1 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S1 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S1
View article: Supplementary Fig S5 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S5 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S5
View article: Supplementary Fig S11 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S11 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S11
View article: Supplementary Fig S10 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S10 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S10
View article: Supplementary Fig S6 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S6 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S6
View article: Supplementary Fig S3 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S3 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S3
View article: Supplementary Fig S1 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S1 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S1
View article: Supplementary Methods from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Methods from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Methods
View article: Supplementary Fig S8 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S8 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S8
View article: Supplementary Fig S4 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S4 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S4
View article: A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
The receptor tyrosine kinase FGFR3 is frequently mutated in bladder cancer and is a validated therapeutic target. Although pan-FGFR tyrosine kinase inhibitors (TKI) have shown clinical efficacy, toxicity and acquired resistance limit the b…
View article: Supplementary Fig S4 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S4 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S4
View article: Supplementary Fig S9 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S9 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S9
View article: Supplementary Fig S2 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S2 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S2
View article: Supplementary Data from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Data from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Table S1
View article: Data from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Data from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
The receptor tyrosine kinase FGFR3 is frequently mutated in bladder cancer and is a validated therapeutic target. Although pan-FGFR tyrosine kinase inhibitors (TKI) have shown clinical efficacy, toxicity and acquired resistance limit the b…
View article: Supplementary Methods from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Methods from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Methods
View article: Supplementary Fig S6 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S6 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S6
View article: Supplementary Fig S8 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S8 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S8
View article: Supplementary Fig S9 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants
Supplementary Fig S9 from A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants Open
Supplementary Fig S9